Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds

News
- 03/07/2019

Ghent, Belgium, and Dresden, Germany: 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR).

The collaboration will combine ConfoBodyTM-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library for the discovery of small molecule GPCR-modulating compounds. Under the terms of the agreement, Confo Therapeutics will gain exclusive, worldwide rights to any drug candidates arising from the collaboration and will be responsible for their development, manufacturing and commercialization.

More info on Confo Therapeutics‘s website.